Literature DB >> 28447156

[Success for a new generation of disease-modifying antirheumatic drugs : The Janus kinase inhibitor baricitinib in rheumatoid arthritis].

G Keyßer1.   

Abstract

Entities:  

Year:  2017        PMID： 28447156     DOI： 10.1007/s00393-017-0307-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  3 in total

1.  Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

Authors:  Gerd R Burmester; Ricardo Blanco; Christina Charles-Schoeman; Jürgen Wollenhaupt; Cristiano Zerbini; Birgitta Benda; David Gruben; Gene Wallenstein; Sriram Krishnaswami; Samuel H Zwillich; Tamas Koncz; Koshika Soma; John Bradley; Charles Mebus
Journal:  Lancet       Date:  2013-01-05       Impact factor: 79.321

2.  The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.

Authors:  Jack G Shi; Xuejun Chen; Fiona Lee; Thomas Emm; Peggy A Scherle; Yvonne Lo; Naresh Punwani; William V Williams; Swamy Yeleswaram
Journal:  J Clin Pharmacol       Date:  2014-12       Impact factor: 3.126

3.  Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

Authors:  Edward C Keystone; Peter C Taylor; Edit Drescher; Douglas E Schlichting; Scott D Beattie; Pierre-Yves Berclaz; Chin H Lee; Rosanne K Fidelus-Gort; Monica E Luchi; Terence P Rooney; William L Macias; Mark C Genovese
Journal:  Ann Rheum Dis       Date:  2014-11-27       Impact factor: 19.103
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.